Komori
Share Issuance and Disposal4598Delta-Fly Pharma,Inc.Pharmaceuticals

Notice Regarding the Monthly Exercise Status of the 11th Series of Stock Acquisition Rights (Stock Acquisition Rights with Provisions for Adjustment of the Exercise Price)

In May 2026, 2,300 of the 11th Stock Acquisition Rights were exercised, and 230,000 new shares were delivered. The number of unexercised rights at month-end was 9,349.

Worth reading
41Recurring
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
230000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Monthly exercise status of stock acquisition rights with an exercise price adjustment clause

発行・処分する株式数

230,000 new shares; 0 treasury shares transferred

Intended allottee
Macquarie Bank Limited (allottee of the previously issued stock acquisition rights)
Terms of the stock acquisition rights
Exercise price
The exercise prices in May 2026 were ¥181, ¥175, ¥150, ¥146, ¥141 and ¥144 per share. Details of the adjustment clause and the floor price: not disclosed
Number of Stock Acquisition Rights
Total issued: 30,000; exercised during the target month: 2,300; unexercised at the end of the target month: 9,349
Procedures under the Corporate Code of Conduct
Describes compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments and Other Matters
Most recent equity financing
The 11th Stock Acquisition Rights issued on 2 February 2026 (stock acquisition rights with exercise price adjustment clauses)
Details of issuance or disposal
ItemDetails
Type of issuance or disposalMonthly exercise status of stock acquisition rights with an exercise price adjustment clause
Number of shares to be issued or disposed of230,000 new shares; 0 treasury shares transferred
Intended allotteeMacquarie Bank Limited (allottee of the previously issued stock acquisition rights)
Total number of issued shares13,995,000 shares (as of the end of the month preceding the target month, including 198 treasury shares) → Not disclosed
Exercise priceThe exercise prices in May 2026 were ¥181, ¥175, ¥150, ¥146, ¥141 and ¥144 per share. Details of the adjustment clause and the floor price: not disclosed
Number of Stock Acquisition RightsTotal issued: 30,000; exercised during the target month: 2,300; unexercised at the end of the target month: 9,349
Procedures under the Corporate Code of ConductDescribes compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments and Other Matters
Most recent equity financingThe 11th Stock Acquisition Rights issued on 2 February 2026 (stock acquisition rights with exercise price adjustment clauses)
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyDilution RateBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the monthly exercise status.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Monthly Exercise Status of the 11th Series of Stock Acquisition Rights (Stock Acquisition Rights with Provisions for Adjustment of the Exercise Price) | Delta-Fly Pharma,Inc. (4598) timely disclosure | Komori